Site Editor

Sandy Srinivas, MD


Neal D. Shore, MD, on New Data on the Safety and Efficacy of Darolutamide in Patients With Prostate Cancer

Posted: Wednesday, March 8, 2023

Neal D. Shore, MD, of Carolina Urologic Research Center/GenesisCare discusses findings from the ARAMIS Rollover study on the use of darolutamide, a second-generation androgen receptor inhibitor, in patients with nonmetastatic castration-resistant prostate cancer. Dr. Shore reviews the safety and tolerability of this treatment, the durability of outcomes, as well as preventing or managing adverse events.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.